SecBot SecBot
6-K ·Filed Nov 10, 2026

BNTX

BioNTech SE
NEUTRAL
Impact 4/10
Horizonweeks Processed6d 14h ago SEC0001776985-26-000083
Notable filing: 6-K
Actionable Insight • Neutral

The acquisition signals BioNTech's intent to file a late-stage oncology asset for FDA approval in the near-to-medium term. Monitor for which specific pipeline candidate will use the voucher and for updates on HSR clearance.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$87.21
T+0 close · Nov 10, 2026 · via day close
Latest settled
+0.50%
T+1 · $87.65
Vs SPY
−0.81%
α at T+1
Next horizon
T+5
in 10h
  1. T+0 · Nov 10 $87.21entry
  2. T+1 · 6d ago +0.50%α −0.81% · $87.65
  3. T+4 · todayOpen
  4. T+5 · in 10h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech announced it will acquire an FDA Priority Review Voucher from Scholar Rock for $205 million in cash. The PRV will be used to support a future regulatory filing for a late-stage oncology asset, potentially accelerating approval timelines.

Key Facts

  • BioNTech agreed to acquire an FDA Priority Review Voucher from Scholar Rock for $205 million in cash.
  • The PRV reduces the FDA review timeline for a single application and could lead to expedited approval.
  • BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline.
  • The transaction is subject to customary closing conditions, including HSR antitrust clearance.

Financial Impact

$205 million cash consideration, representing approximately 0.9% of BioNTech's $22.0 billion market cap.

cash

Risk Factors

  • The transaction is subject to HSR antitrust clearance and other customary closing conditions.
  • The specific asset that will use the PRV has not been disclosed, making it difficult to assess the potential value of the accelerated review.
  • A PRV only reduces review time; it does not guarantee approval or affect the clinical data required for approval.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
69% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000083
Document: a991261109_prvxbntstatement.htm0001776985-26-000083
Document: 0001776985-26-000083-index-headers.html0001776985-26-000083
Document: 0001776985-26-000083-index.html0001776985-26-000083
Document: 0001776985-26-000083.txt0001776985-26-000083
Earnings Context (Synthetic; results releases only)0001776985-26-000083

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Viewing Entry $87.21 Now $85.60 −1.85% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026